Today: 13 May 2026
Browse Category

Pharmaceuticals 13 February 2026 - 24 February 2026

Novo Nordisk stock slips again as CagriSema miss drives forecast cuts and puts next catalysts in focus

Novo Nordisk stock slips again as CagriSema miss drives forecast cuts and puts next catalysts in focus

Novo Nordisk shares fell 2.5% to 245.1 Danish crowns Tuesday after its CagriSema obesity drug failed to match Eli Lilly’s tirzepatide in a Phase 3 trial. Barclays cut its peak sales forecast for CagriSema to $2 billion from $12 billion. Novo also reported mid-stage China trial results for its “triple G” obesity drug UBT251, showing up to 19.7% weight loss after 24 weeks.
24 February 2026
··
Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Eli Lilly shares climbed nearly 5% late Monday after Novo Nordisk reported its obesity drug CagriSema underperformed Lilly’s Zepbound in a head-to-head trial. Novo’s U.S.-listed shares dropped over 16%. CagriSema showed 23% weight loss after 84 weeks, compared to 25.5% for Zepbound. The trial failed to prove CagriSema was not worse than tirzepatide on weight loss.
23 February 2026
····
Organon stock jumps in premarket after MIUDELLA licensing deal, with 10-K filing in focus

Organon stock jumps in premarket after MIUDELLA licensing deal, with 10-K filing in focus

Organon shares jumped 7.8% to $8.10 in premarket trading Monday after the company announced a global licensing deal for MIUDELLA, a hormone-free copper IUD from Sebela Pharmaceuticals. Organon agreed to pay $27.5 million upfront and up to $505 million in sales-based milestones, pending antitrust and FDA approvals. The company’s dividend record date is Monday, with payment set for March 12.
23 February 2026
··
Vanda Pharmaceuticals stock jumps premarket after FDA clears Bysanti — what to watch at the open

Vanda Pharmaceuticals stock jumps premarket after FDA clears Bysanti — what to watch at the open

Vanda Pharmaceuticals shares jumped 33% to $7.68 in premarket trading Monday after the FDA approved its new antipsychotic pill, Bysanti, late Friday. The drug, milsaperidone, is bioequivalent to Vanda’s existing Fanapt and will be available commercially in the third quarter of 2026. Traders are watching whether the rally holds at the open and how Bysanti will compete in a crowded market.
23 February 2026
··
Johnson & Johnson stock price: JNJ heads into Monday as Tremfya data lands and dividend date nears

Johnson & Johnson stock price: JNJ heads into Monday as Tremfya data lands and dividend date nears

Johnson & Johnson shares closed at $242.49 on Friday, down 1.8%. The company released new three-year Tremfya data in ulcerative colitis over the weekend. J&J stock goes ex-dividend Feb. 24, with a $1.30-per-share payout set for March 10. A potential $20 billion sale of its DePuy Synthes orthopedics unit remains under discussion.
22 February 2026
···
Johnson & Johnson stock price: JNJ heads into Monday with DePuy sale talk and Tremfya data

Johnson & Johnson stock price: JNJ heads into Monday with DePuy sale talk and Tremfya data

Johnson & Johnson shares fell 1.8% to $242.49 Friday after Reuters reported the company is preparing a potential $20 billion sale of its DePuy Synthes orthopedics unit. J&J released new long-term data for Tremfya in ulcerative colitis, showing 80.8% remission at week 140. The company did not comment on the reported DePuy sale. Investors await management updates in March and April.
21 February 2026
··
GSK share price slips as Arexvy RSV data lands and stock goes ex-dividend

GSK share price slips as Arexvy RSV data lands and stock goes ex-dividend

GSK shares fell 0.4% in early London trading Thursday after the company released new real-world data on its RSV vaccine Arexvy and the stock went ex-dividend. A U.S. study linked Arexvy to reduced RSV-related hospitalisations and lower rates of major cardiovascular events in adults over 60. GSK also bought back 420,000 shares on Feb. 17. Investors await further RSV data and updates on dividends.
19 February 2026
····
Why CSL’s share price is moving: Lilly clazakizumab deal, buyback pace and the next dividend date

Why CSL’s share price is moving: Lilly clazakizumab deal, buyback pace and the next dividend date

CSL shares closed up 0.95% at A$154.19 in Sydney, marking a second consecutive gain after announcing a US$100 million licensing deal with Eli Lilly for clazakizumab. ASX filings showed CSL continued its share buyback and a director increased holdings. The stock remains about 15% below early-February levels. CEO Paul McKenzie is set to retire, with Gordon Naylor named interim chief.
19 February 2026
···
Why GSK stock is moving today: Exdensur EU nod and a fresh buyback

Why GSK stock is moving today: Exdensur EU nod and a fresh buyback

GSK shares rose 1.1% to 2,263 pence after the European Commission approved its twice-yearly asthma drug Exdensur and the company launched a new tranche of share buybacks. GSK will repurchase up to £0.45 billion in shares by April 24. The company also reported new real-world data showing its RSV vaccine Arexvy was 75.6% effective against RSV-related hospitalisation in adults over 60.
18 February 2026
··
Eli Lilly stock in focus as Retevmo lung cancer trial meets endpoint, with trading back Tuesday

Eli Lilly stock in focus as Retevmo lung cancer trial meets endpoint, with trading back Tuesday

Eli Lilly reported its cancer drug Retevmo beat placebo on event-free survival in a Phase 3 trial for early-stage RET fusion-positive non-small cell lung cancer. U.S. markets are closed for Presidents Day, delaying any stock reaction until Tuesday. Lilly shares last closed at $1,040, up 0.2% Friday. Full trial data will be presented at a future medical meeting.
16 February 2026
··
AbbVie stock ends higher Friday; what traders watch for ABBV after the Presidents Day break

AbbVie stock ends higher Friday; what traders watch for ABBV after the Presidents Day break

AbbVie shares closed up 1.8% at $231.50 Friday, outpacing Johnson & Johnson. U.S. markets will be closed Monday for Presidents Day, with trading set to resume Tuesday. Investors are weighing AbbVie’s drug-pricing moves and pipeline as the company shifts away from Humira after patent loss. Trading volume topped its recent average, with the stock about 5% below its 52-week high.
15 February 2026
··
Healthcare stocks head into Presidents Day break after Dexcom, Moderna lift XLV

Healthcare stocks head into Presidents Day break after Dexcom, Moderna lift XLV

The Health Care Select Sector SPDR Fund (XLV) rose 1.1% to $157.67 Friday, led by Dexcom’s 7.6% jump and Moderna’s 5.3% gain after earnings. Dexcom beat Q4 estimates and reiterated its 2026 outlook, while Moderna forecast up to 10% revenue growth, citing overseas markets. Broader markets saw tech lag as inflation data cooled. U.S. exchanges close Monday for Presidents Day.
15 February 2026
··
Vertex stock jumps nearly 6% on Oppenheimer upgrade as traders size up new drug pipeline

Vertex stock jumps nearly 6% on Oppenheimer upgrade as traders size up new drug pipeline

Vertex shares jumped 5.7% to $491.47 Friday after Oppenheimer upgraded the stock, citing growth plans beyond cystic fibrosis. The company set 2026 revenue guidance at up to $13.1 billion, with at least $500 million expected from new products. Vertex highlighted gene-editing, pain, and kidney therapies in its outlook. U.S. markets close Monday for Presidents Day.
14 February 2026
··
Moderna stock price jumps late after earnings beat, but FDA flu setback hangs over MRNA

Moderna stock price jumps late after earnings beat, but FDA flu setback hangs over MRNA

Moderna shares climbed 5% to $42.23 in after-hours trading Friday after beating fourth-quarter revenue estimates and reaffirming its 2026 growth outlook. The FDA refused to file Moderna’s flu vaccine application, prompting the company to seek a Type A meeting. The flu shot is under review in Europe, Canada, and Australia. Moderna reported Q4 revenue of $678 million and a $2.11 per share loss.
13 February 2026
····
Merck stock pops on Deutsche Bank upgrade — what to watch ahead of ASCO GU

Merck stock pops on Deutsche Bank upgrade — what to watch ahead of ASCO GU

Merck shares climbed 1.8% to $121.41 in after-hours trading Friday after Deutsche Bank upgraded the stock and raised its price target. The move comes ahead of key cancer study results set for release at the ASCO Genitourinary Cancers Symposium later this month. Merck’s chief marketing officer sold 10,000 shares on Feb. 12. U.S. markets are closed Monday for Washington’s Birthday; trading resumes Tuesday.
13 February 2026
··
Eli Lilly stock price climbs as $1.5 billion pill stockpile sharpens focus on FDA April decision

Eli Lilly stock price climbs as $1.5 billion pill stockpile sharpens focus on FDA April decision

Eli Lilly shares rose 0.6% to $1,044.62 after the company disclosed $1.5 billion in pre-launch inventory for its experimental obesity pill, orforglipron, ahead of an expected FDA decision in April. The company also repurchased $4.1 billion in shares in 2025 and raised its quarterly dividend. Chinese regulators approved Lilly’s mirikizumab for Crohn’s disease and ulcerative colitis. U.S. stocks slipped in midday trading.
13 February 2026
··
1 2 3 4 5 6 … 40

Stock Market Today

  • SoFi Acquires PrimaryBid IPO Tool Amid Mixed Market Reactions
    May 13, 2026, 4:30 PM EDT. SoFi Technologies acquired PrimaryBid's IPO allocation technology to boost its presence in capital markets for retail investors. Despite this strategic move, shares fell 2.9% to $15.44 after Truist cut the price target from $20 to $17, citing concerns in both loan and technology segments. The acquisition ends PrimaryBid's run as an independent fintech and marks SoFi's deeper push into IPO access, where competitors like Robinhood also operate. SoFi posted strong Q1 results with a 43% revenue jump to $1.10 billion and increased members by 35%, yet a 16% fall in technology platform accounts and cautious Q2 revenue guidance suggest challenges ahead. Investors remain wary amid persistent rate pressures impacting consumer lenders.

Latest articles

Applied Optoelectronics Stock Surges Again as AI Data-Center Demand Outruns Supply

Applied Optoelectronics Stock Surges Again as AI Data-Center Demand Outruns Supply

13 May 2026
Applied Optoelectronics shares surged 21% Wednesday, trading at $227.05 after strong demand from AI data centers pushed first-quarter data-center revenue to $81.4 million, up from $32 million a year ago. CFO Stefan Murry said supply remains the main constraint, with demand expected to outpace output through mid-2027. AOI shipped its first volume 800G products to a hyperscale customer. The company posted a first-quarter net loss of $14.3 million.
Dow Jones Today: Why the Dow Slipped While AI Stocks Drove Wall Street Higher

Dow Jones Today: Why the Dow Slipped While AI Stocks Drove Wall Street Higher

13 May 2026
The Dow Jones Industrial Average fell 90.72 points to 49,669.84 on Wednesday, while the S&P 500 and Nasdaq rose, lifted by gains in chip and AI stocks. Producer prices jumped 1.4% in April, the largest monthly increase since March 2022. The Senate confirmed Kevin Warsh as Federal Reserve chair in a 54-45 vote. Prediction markets showed a 97% chance the Fed holds rates steady in June.
US Stocks Hit Fresh Records as Chip Rally Overpowers Hot Inflation Shock

US Stocks Hit Fresh Records as Chip Rally Overpowers Hot Inflation Shock

13 May 2026
The S&P 500 closed at 7,444.14 and the Nasdaq at 26,404.74, both record highs, while the Dow slipped 0.13% to 49,693.63. April producer prices jumped 1.4%, the largest monthly rise since March 2022, pushing back Fed rate-cut expectations. Prediction markets now see a long pause in U.S. policy easing. Tech stocks, especially AI-linked shares, led gains despite the inflation surprise.

Popular

Nebius Stock’s Pre-Market Bounce Puts the AI Factory Trade Back on Trial

Nebius Stock’s Pre-Market Bounce Puts the AI Factory Trade Back on Trial

13 May 2026
Nebius Group shares rose 3.53% to $185.42 in early extended trading after a 3.76% drop Tuesday, ahead of its Q1 earnings release. The company broke ground on a gigawatt-scale AI factory in Missouri and announced a technology deal with Clarifai’s founder and team. NBIS is up 32.79% in the past month and 454.18% over the past year. Investors are weighing rapid expansion against ongoing losses and heavy capital spending.
Go toTop